No mistake in reducing blood sugar and weight -- xulophy, a Novo Nordisk Diabetes cocktail, has been approved by the European Union

Source: Novo Nordisk Diabetes cocktail xulophy (IDEG lira) was recently approved by the European Union for the treatment of adult patients with type 2 diabetes on September 22, 2014 Xultophy is the first long-acting insulin and GLP-1 receptor agonist compound In clinical trials, xultophy not only significantly improves blood glucose level, but also provides significant weight-loss effect Xulophy is composed of tresiba (insulin deglucec) and Victoza (liraglutide) Tresiba is a long-acting basic insulin, and Victoza is a glucagon like peptide 1 (GLP-1) receptor agonist, which can stimulate the secretion of natural insulin Last year, the FDA refused to approve tresiba due to cardiovascular risk and informed Novo Nordisk that it would not be able to resubmit its listing application until it submitted long-term prognosis data to prove the safety of tresiba Novo Nordisk predicts that tresiba will not be available in the US until 2017 In addition, according to FDA requirements, any compound product must be composed of two or more approved drugs, so it is not known when xultophy will land in the United States Victoza is the heavyweight drug of Novo Nordisk, with annual sales of up to $2 billion, which is the largest in GLP-1 market The industry forecasts that xultophy's annual sales peak will exceed US $1 billion, and the drug will become the next heavyweight product of Novo Nordisk However, there is no timetable for when tresiba will be approved by FDA, so it is difficult to determine the real potential of xeltophy, but there is no doubt that the future of xeltophy is limitless! The development of new diabetes drugs has become the focus of biotechnology, especially GLP-1 receptor agonists At present, the competition in GLP-1 field is increasingly fierce There are Victoza (liraglutide, once a day) of Novo Nordisk, Byetta (exenatide, exenatide, twice a day) and bydureon (long-term sustained release exenatide, once a week) of Bristol Myers Squibb and AstraZeneca, and lyxumia (lixisentide) of Sanofi on the market , risiratide, once a day), tanzeum / eperzan (albiglutide, abilutide, once a week) of GlaxoSmithKline Yesterday, the FDA approved Lilly's new diabetes drug, dulaglutide (once a week), which is also a GLP-1 receptor agonist In clinical trials, it has the same effect as Novo Nordisk's Victoza, but Victoza is injected once a day, while the weekly injection of trucity has more advantages, which will become the selling point of Lilly's marketing The drug will become Victoza A replacement for Industry forecasts that trulicity's sales will reach US $1.3 billion in 2020.